In the past week, SNSE stock has gone down by -7.98%, with a monthly gain of 8.28% and a quarterly plunge of -19.19%. The volatility ratio for the week is 9.64%, and the volatility levels for the last 30 days are 17.89% for Sensei Biotherapeutics Inc The simple moving average for the last 20 days is -9.65% for SNSE’s stock, with a simple moving average of -37.07% for the last 200 days.
Is It Worth Investing in Sensei Biotherapeutics Inc (NASDAQ: SNSE) Right Now?
Moreover, the 36-month beta value for SNSE is 0.13. Analysts have varying opinions on the stock, with 3 analysts rating it as a “buy,” 4 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for SNSE is 16.54M and currently, short sellers hold a 1.18% of that float. On November 14, 2024, SNSE’s average trading volume was 314.18K shares.
SNSE) stock’s latest price update
Sensei Biotherapeutics Inc (NASDAQ: SNSE) has experienced a decline in its stock price by -6.49 compared to its previous closing price of 0.53. However, the company has seen a fall of -7.98% in its stock price over the last five trading days. globenewswire.com reported 2024-11-14 that – SNS-101 Phase 1/2 dose expansion clinical data expected in the first half of 2025 – – Organizational restructuring to focus resources on advancing the clinical development of SNS-101 – – Cash runway extended into the second quarter of 2026 – BOSTON, Nov. 14, 2024 (GLOBE NEWSWIRE) — Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients, today reported financial results for the third quarter ended September 30, 2024, and provided corporate updates. “The third quarter of 2024 saw significant progress in advancing patient enrollment in the dose expansion portion of the Phase 1 study for SNS-101 across dose levels and patients with primary and acquired resistance to PD-1 inhibitors.
Analysts’ Opinion of SNSE
Many brokerage firms have already submitted their reports for SNSE stocks, with Stephens repeating the rating for SNSE by listing it as a “Overweight.” The predicted price for SNSE in the upcoming period, according to Stephens is $5 based on the research report published on May 14, 2024 of the current year 2024.
Berenberg, on the other hand, stated in their research note that they expect to see SNSE reach a price target of $12. The rating they have provided for SNSE stocks is “Hold” according to the report published on July 01st, 2021.
Oppenheimer gave a rating of “Perform” to SNSE, setting the target price at $14 in the report published on June 29th of the previous year.
SNSE Trading at -4.98% from the 50-Day Moving Average
After a stumble in the market that brought SNSE to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -74.38% of loss for the given period.
Volatility was left at 17.89%, however, over the last 30 days, the volatility rate increased by 9.64%, as shares surge +15.65% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -16.95% lower at present.
During the last 5 trading sessions, SNSE fell by -9.28%, which changed the moving average for the period of 200-days by -40.24% in comparison to the 20-day moving average, which settled at $0.5497. In addition, Sensei Biotherapeutics Inc saw -28.18% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for SNSE
Current profitability levels for the company are sitting at:
- -11.41 for the present operating margin
- 0.86 for the gross margin
The net margin for Sensei Biotherapeutics Inc stands at -10.47. The total capital return value is set at -0.68. Equity return is now at value -45.17, with -39.73 for asset returns.
Based on Sensei Biotherapeutics Inc (SNSE), the company’s capital structure generated 0.09 points at debt to capital in total, while cash flow to debt ratio is standing at -5.6. The debt to equity ratio resting at 0.1. The interest coverage ratio of the stock is -391.35.
Currently, EBITDA for the company is -33.39 million with net debt to EBITDA at 0.49. When we switch over and look at the enterprise to sales, we see a ratio of -1.02. The liquidity ratio also appears to be rather interesting for investors as it stands at 10.90.
Conclusion
To wrap up, the performance of Sensei Biotherapeutics Inc (SNSE) has been bad in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
